Impact of visceral obesity on cardiac parasympathetic activity in type 2 diabetics after coronary artery bypass graft surgery

Obesity

Volumn 21, Issue 8, 2013, Pages 1578-1585

  Salamin, Guillaume ^a,b   Pelletier, Claudine ^a,b   Poirier, Paul ^a,b   Després, Jean Pierre ^a,b   Bertrand, Olivier ^b   Alméras, Natalie ^b   Costerousse, Olivier ^b   Brassard, Patrice ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; CORONARY ARTERY BYPASS GRAFT; CORRELATION ANALYSIS; DISEASE ASSOCIATION; HEART RATE VARIABILITY; HUMAN; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARASYMPATHETIC TONE; STATISTICAL ANALYSIS; SUBCUTANEOUS FAT; WAIST CIRCUMFERENCE;

ADIPOKINES; ADIPOSITY; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; CORONARY ARTERY BYPASS; DIABETES MELLITUS, TYPE 2; HEART RATE; HUMANS; INSULIN; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MULTIVARIATE ANALYSIS; OBESITY, ABDOMINAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; SUBCUTANEOUS FAT; TOMOGRAPHY, X-RAY COMPUTED; WAIST CIRCUMFERENCE;

EID: 84883170153     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20089     Document Type: Article

References (40)

1. Hu G, Jousilahti P, Qiao Q, Katoh S, Tuomilehto J,. Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. Diabetologia 2005; 48: 856-861.
2. Hossain P, Kawar B, El Nahas M,. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med 2007; 356: 213-215.
3. La Rovere MT, Pinna GD, Hohnloser SH, et al. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation 2001; 103: 2072-2077.
4. Liao D, Carnethon M, Evans GW, Cascio WE, Heiss G,. Lower heart rate variability is associated with the development of coronary heart disease in individuals with diabetes: the atherosclerosis risk in communities (ARIC) study. Diabetes 2002; 51: 3524-3531.
5. Mathieu P, Pibarot P, Larose E, Poirier P, Marette A, Despres JP,. Visceral obesity and the heart. Int J Biochem Cell Biol 2008; 40: 821-836.
6. Ritchie SA, Connell JM,. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis 2007; 17: 319-326.
7. Cartier A, Bergeron J, Poirier P, et al. Increased plasma interleukin-1 receptor antagonist levels in men with visceral obesity. Ann Med 2009; 41: 471-478.
8. Alvarez GE, Beske SD, Ballard TP, Davy KP,. Sympathetic neural activation in visceral obesity. Circulation 2002; 106: 2533-2536.
9. Laederach-Hofmann K, Mussgay L, Ruddel H,. Autonomic cardiovascular regulation in obesity. J Endocrinol 2000; 164: 59-66.
10. Rissanen P, Franssila-Kallunki A, Rissanen A,. Cardiac parasympathetic activity is increased by weight loss in healthy obese women. Obes Res 2001; 9: 637-43.
11. Katsuki A, Urakawa H, Gabazza EC, et al. Circulating levels of active ghrelin is associated with abdominal adiposity, hyperinsulinemia and insulin resistance in patients with type 2 diabetes mellitus. Eur J Endocrinol 2004; 151: 573-577.
12. Lambert E, Lambert G, Ika-Sari C, et al. Ghrelin modulates sympathetic nervous system activity and stress response in lean and overweight men. Hypertension 2011; 58: 43-50.
13. Despres JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001; 322: 716-720.
14. Smith JW, Marcus FI, Serokman R,. Prognosis of patients with diabetes mellitus after acute myocardial infarction. Am J Cardiol 1984; 54: 718-721.
15. Bertrand OF, Poirier P, Rodes-Cabau J, et al. A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial. Can J Cardiol 2009; 25: 509-515.
16. Bertrand OF, Poirier P, Rodes-Cabau J, et al. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: a randomized placebo-controlled clinical trial. Atherosclerosis 2010; 211: 565-573.
17. Levy JC, Matthews DR, Hermans MP,. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998; 21: 2191-2192.
18. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 1996; 17: 354-381.
19. Poirier P, Hernandez TL, Weil KM, Shepard TJ, Eckel RH,. Impact of diet-induced weight loss on the cardiac autonomic nervous system in severe obesity. Obes Res 2003; 11: 1040-1047.
20. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. National Institutes of Health. Obes Res 1998; 6 Suppl 2: 51S-209S.
21. Pare A, Dumont M, Lemieux I, et al. Is the relationship between adipose tissue and waist girth altered by weight loss in obese men? Obes Res 2001; 9: 526-534.
22. Nesto R, Libby P,. Diabetes mellitus and the cardiovascular system. 2001. In: Heart Disease: A Textbook of Cardiovascular Medicine, Braunwald E, Zipes DP, Libby P, (eds). Philadelphia, PA: WB Saunders: 2001. pp 2133-2150.
23. Kataoka M, Ito C, Sasaki H, Yamane K, Kohno N,. Low heart rate variability is a risk factor for sudden cardiac death in type 2 diabetes. Diabetes Res Clin Pract 2004; 64: 51-58.
24. Smith SC, Jr., Faxon D, Cascio W, et al. Prevention conference VI: diabetes and cardiovascular disease: writing group VI: revascularization in diabetic patients. Circulation 2002; 105: e165-e169.
25. Niemela MJ, Airaksinen KE, Tahvanainen KU, Linnaluoto MK, Takkunen JT,. Effect of coronary artery bypass grafting on cardiac parasympathetic nervous function. Eur Heart J 1992; 13: 932-935.
26. Alvarez GE, Ballard TP, Beske SD, Davy KP,. Subcutaneous obesity is not associated with sympathetic neural activation. Am J Physiol Heart Circ Physiol 2004; 287: H414-H418.
27. Girerd N, Pibarot P, Fournier D, et al. Middle-aged men with increased waist circumference and elevated C-reactive protein level are at higher risk for postoperative atrial fibrillation following coronary artery bypass grafting surgery. Eur Heart J 2009; 30: 1270-1278.
28. Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS,. Atrial fibrillation and obesity-results of a meta-analysis. Am Heart J 2008; 155: 310-315.
29. Despres JP, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008; 28: 1039-1049.
30. Lampert R, Bremner JD, Su S, et al. Decreased heart rate variability is associated with higher levels of inflammation in middle-aged men. Am Heart J 2008; 156: 759 e1-759 e7.
31. Kanter JE, Johansson F, LeBoeuf RC, Bornfeldt KE,. Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques? Circ Res 2007; 100: 769-781.
32. Perticone F, Ceravolo R, Candigliota M, et al. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes 2001; 50: 159-165.
33. Laurent S, Kingwell B, Bank A, Weber M, Struijker-Boudier H,. Clinical applications of arterial stiffness: therapeutics and pharmacology. Am J Hypertens 2002; 15: 453-458.
34. Harris KF, Matthews KA,. Interactions between autonomic nervous system activity and endothelial function: a model for the development of cardiovascular disease. Psychosom Med 2004; 66: 153-164.
35. Despres JP, Lemieux I,. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887.
36. Iacobellis G, Assael F, Ribaudo MC, et al. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res 2003; 11: 304-310.
37. Rabkin SW,. Epicardial fat: properties, function and relationship to obesity. Obes Rev 2007; 8: 253-261.
38. Cameron NE, Cotter MA,. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997; 46 Suppl 2: S31-S37.
39. Ziegler D,. Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. Diabetes Metab Rev 1994; 10: 339-383.
40. Surwit RS, Feinglos MN,. Stress and autonomic nervous system in type II diabetes. A hypothesis. Diabetes Care 1988; 11: 83-85.